Integrins and adhesion molecules as targets to treat inflammatory bowel disease.

Abstract

Inflammatory bowel diseases (IBD) present a typically relapsing-remitting behavior and are characterized by a disabling and progressive course. Anti-tumor necrosis factor (TNF)-α agents have drastically changed the therapeutic management of IBD. However, a significant proportion of patients does not have a primary response, some patients lose response overtime and/or experience side effects. Recently, anti-adhesion molecules were investigated and showed efficacy with a good safety profile. Vedolizumab was recently approved for both Crohn's disease (CD) and ulcerative colitis (UC) and several other molecules are under evaluation in this field. Anti-adhesion molecules could represent a potential therapeutic option for future therapy in IBD. In this review we report the efficacy and safety of major anti-adhesion drugs in active IBD patients.

• Authors: Ivana Bravatà, Mariangela Allocca, Gionata Fiorino, Silvio Danese
• Journal: Current opinion in pharmacology (Curr Opin Pharmacol) Vol. 25 Pg. 67-71 (Dec 2015) ISSN: 1471-4973 [Electronic] England
• PMID: 26687159 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015. Published by Elsevier Ltd.

Chemical References

• Antibodies, Monoclonal, Humanized
• Cell Adhesion Molecules
• Integrins

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Cell Adhesion Molecules (antagonists & inhibitors)
• Humans
• Inflammatory Bowel Diseases (drug therapy, metabolism)
• Integrins (antagonists & inhibitors)
• Models, Biological
• Molecular Targeted Therapy (methods)